Comparison of hepatosteatosis in mice treated with two forms of asparaginase: Orgel and Mittelman

Calaspargase-pegol (SC-PEG) has replaced pegaspargase (SS-PEG) in
pediatric ALL regimens in the United States. Calaspargase-pegol’s greater
drug exposure has raised concern for correspondingly increased
hepatotoxicity.  However, we found no difference in
hepatosteatosis between formulations in obese and non-obese
asparaginase-treated mice. These reassuring findings should be confirmed
in clinical studies.